Brind.

FDA Extends Review Period for Belite Bio's Stargardt Disease Drug

1 report, 1 independent Updated Fri 13:45
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

The U.S. Food and Drug Administration informed Belite Bio, Inc. that it has extended the review period for the New Drug Application (NDA) for tinlarebant by three months. The extended action date is now May 12, 2027. If no major deficiencies are found during the review, the FDA plans to communicate proposed labeling requests by April 12, 2027.

From manilatimes.net

Why it matters

Some supportBrind's analysis of the reports

The extension provides the FDA with additional time to review the clinical evidence supporting tinlarebant, an oral therapy intended to treat Stargardt disease type 1. The timeline for this drug's potential market entry is now adjusted.

From manilatimes.net

Who's involved

  • FDAThe regulatory agency that extended the review period for the drug application.

Possible ripples

Who this could reach next, traced step by step from the reporting. Possibilities worth considering, not forecasts.

Keep exploring

The entities involved

Related events

Coverage

Newest first; wire copies grouped